Biotech

All Articles

Merck quits stage 3 TIGIT trial in bronchi cancer for futility

.Merck &amp Co.'s TIGIT course has suffered yet another drawback. Months after shuttering a stage 3 ...

After a tough year, Exscientia folds into Recursion

.After a year defined through pipe hairstyles, the variation of its CEO as well as unemployments, Ex...

Cullinan, after $25M package, hands back bispecific to Harbour

.Cullinan Rehab was wowed sufficient along with Port BioMed's bispecific immune reactor that it gave...

A nearer look at Ferocious Biotech's Ferocious 15

.In this week's incident of "The Leading Pipe," our team are actually diving into Brutal Biotech's a...

Lilly experiences period 2 failure of tau-targeting med

.The confetti is still flying coming from Eli Lilly's celebration celebrating the commendation of Al...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our roundup of substantial management hirings, firings and r...

Lykos will certainly talk to FDA to reevaluate its decision following turndown of MDMA treatment for trauma

.Observing a poor revealing for Lykos Rehabs' MDMA applicant for post-traumatic stress disorder at a...

AN 2 halves census, quits stage 3 test after data dissatisfy

.AN2 Therapies is reviewing its own organization in reaction to lackluster midphase data, swearing t...

Merck spends $700M for bispecific, spying autoimmune position and chance to challenge Amgen in cancer

.Merck &amp Co. is actually paying out $700 thousand beforehand to challenge Amgen in a blood stream...

Gilead spends J&ampJ $320M to exit licensing deal for seladelpar

.With Gilead Sciences on the verge of an FDA selection for its liver condition medication seladelpar...